Stockscreener 앱 받기
54.03
0.96%
0.485
전일 마감가:
$53.55
열려 있는:
$53.81
하루 거래량:
450.73K
Relative Volume:
0.14
시가총액:
$23.93B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
28.30
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
+2.30%
1개월 성능:
+8.74%
6개월 성능:
+38.91%
1년 성능:
+67.33%
1일 변동 폭
$53.69
$54.23
1주일 범위
$51.81
$54.23
52주 변동 폭
$32.15
$54.23
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
53.99 | 23.74B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
436.70 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
637.31 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.37 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.75 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.32 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma PLC $RPRX Shares Bought by Handelsbanken Fonder AB - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 13,684 Shares of Stock - MarketBeat
Royalty Pharma EVP Marshall Urist sells $721,837 in shares - Investing.com
Royalty Pharma EVP Marshall Urist sells $721,837 in shares By Investing.com - Investing.com Canada
Royalty Pharma (RPRX) EVP Urist sells 13,684 shares in 10b5-1 planned trade - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month HighWhat's Next? - MarketBeat
Royalty Pharma stock hits 52-week high at 53.48 USD - Investing.com
Fideuram Intesa Sanpaolo Private Banking S.P.A. Invests $4.92 Million in Royalty Pharma PLC $RPRX - MarketBeat
Thrivent Financial for Lutherans Acquires 22,015 Shares of Royalty Pharma PLC $RPRX - MarketBeat
49,855 Shares in Royalty Pharma PLC $RPRX Acquired by Partners Group Holding AG - MarketBeat
Marathon Asset Management Ltd Has $15 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Acquired by Cullen Frost Bankers Inc. - MarketBeat
RPRX: Royalty financing is rapidly growing, with flexible deals and global expansion fueling future growth - TradingView
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance - Insider Monkey
Royalty Pharma plc (RPRX) Investor Outlook: Strong Buy Ratings and Solid Growth Prospects - DirectorsTalk Interviews
Qsemble Capital Management LP Invests $2.88 Million in Royalty Pharma PLC $RPRX - MarketBeat
Commerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead - Seeking Alpha
Royalty Pharma EVP Urist sells $726,137 in shares - Investing.com UK
Royalty Pharma EVP Urist sells $726,137 in shares By Investing.com - Investing.com Nigeria
Royalty Pharma (RPRX) EVP sells 13,684 shares under 10b5-1 plan - Stock Titan
Rule 10b5-1 sale by Royalty Pharma (RPRX) director Gregory Norden - Stock Titan
Understanding the Setup: (RPRX) and Scalable Risk - Stock Traders Daily
Press Release: Royalty Pharma Declares Second Quarter 2026 Dividend - Moomoo
Royalty Pharma (NASDAQ: RPRX) insider sale notice — 3,045 shares - Stock Titan
[144] Royalty Pharma plc SEC Filing - Stock Titan
Capital International (RPRX) amendment shows 8.8% stake in Royalty Pharma - Stock Titan
Royalty Pharma (RPRX) Valuation Check After Strong Q1 Earnings And Rising Investor Interest - Sahm
Royalty Pharma stock hits 52-week high at 52.16 USD By Investing.com - Investing.com Nigeria
RPRX: Expanding royalty financing, robust pipeline, and strong capital position drive future growth - TradingView
Royalty Pharma stock hits 52-week high at 52.16 USD - Investing.com India
Royalty pharma – funding the next generation of medicines - Livewire Markets
RPRX SEC FilingsRoyalty Pharma Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon - Yahoo Finance
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Healthcare Giant with a Promising 16.66% Potential Upside - DirectorsTalk Interviews
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Accelerated Royalty Deals and Dividend Hike Could Be A Game Changer For Royalty Pharma (RPRX) - simplywall.st
MSN Money - MSN
Royalty Pharma (NASDAQ:RPRX) Upgraded at Wall Street Zen - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
Christopher Hite gains 24,263 Royalty Pharma (RPRX) shares via equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 18,197-share equity award - Stock Titan
10% Of This Royalty Pharma Insider's Holdings Were Sold - Yahoo Finance
Royalty Pharma raises 2026 portfolio receipts guidance to $3.325B-$3.45B as it scales R&D co-funding - MSN
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Citigroup Raises Royalty Pharma (NASDAQ:RPRX) Price Target to $66.00 - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
1.20%
자본화:
|
볼륨(24시간):